PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Thromb Res. Author manuscript; available in PMC 2011 December 26.
Published in final edited form as:
PMCID: PMC3245964
NIHMSID: NIHMS281808

Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation

Abstract

Radiofrequency catheter ablation is being used with increasing frequency as a strategy to manage atrial fibrillation. Patients undergoing this procedure are at increased short-term risk of thromboembolism for several days and up to 4 weeks or longer after their ablation, and anticoagulation management surrounding the ablation procedure remains controversial. Although no conclusive recommendations can be made, published guidelines and data support therapeutic anticoagulation with warfarin for 3 weeks prior and intravenous heparin during the ablation. Warfarin may either be continued through the ablation or stopped 2–5 days prior. If the latter approach is chosen, a pre-ablation bridging strategy of enoxaparin 1 mg/kg twice daily is reasonable in selected patients unless the patient’s bleeding risk dictates using a lower dose regimen (0.5 mg/kg twice daily) or avoiding bridging altogether. Fewer data are available for post-ablation management strategies, and current practice patterns are based largely on single-center experiences in smaller, non-randomized studies. For lower risk patients (CHADS2 0–1), either warfarin or aspirin may be utilized without bridging. In higher thromboembolic risk patients (CHADS2 ≥ 2), either enoxaparin (1 mg/kg twice daily) or heparin may be started within the first 12–24 h post-procedure. For patients with bleeding risk factors, enoxaparin may be subsequently reduced to 0.5 mg/kg until the INR is therapeutic, although the efficacy of this lower dosing regimen has not been well studied. In accordance with national guidelines, warfarin should be continued post-ablation for a minimum of 2 months and then indefinitely in patients with a CHADS2 score ≥ 2.

Keywords: Atrial Fibrillation, Ablation, Anticoagulation, Low-molecular weight heparin, Unfractionated heparin, Warfarin, Peri-procedural, Bridging, Stroke, Transient Ischemic Attack, Thromboembolism

Atrial fibrillation (AF) is one of the most common, sustained arrhythmias and is associated with significant morbidity and mortality. Although there is still controversy regarding the best management approach to AF, most providers choose a strategy of either ventricular rate or rhythm control along with chronic anticoagulation to prevent thromboembolic (TE) complications [1]. More recently, in addition, or at times, as an alternative to these approaches, catheter-directed ablation is being used with increasing frequency in patients with symptomatic, refractory AF.

Regardless of what strategy is used, AF may result in TE - often from thrombus in the left atrium or atrial appendage - and accounts for nearly 15% of all strokes in the US [2], with an annual incidence of stroke of up to 6% or even higher in some patients [3]. The risk of stroke in AF is neither static nor uniform, may depend on both clinical and echocardiographic factors, and usually requires an individualized approach to assess stroke risk and determine appropriate AC management. Re-estimation of the estimated stroke risk is recommended as a patient's risk may change over time, and alternative therapy may be indicated.

Although recent meta-analysis data failed to identify one particular stroke risk assessment scoring system that is clearly superior to other validated systems[4], the CHADS2 score is commonly used to assess baseline stroke-risk and guide antithrombotic therapy (Table 1) [5]. Most of the published reports of peri-ablation anticoagulation reviewed in this paper utilized the CHADS2 scoring system and thus, we will also use this same risk assessment tool. In patients with a CHADS2 score of ≥ 2, warfarin effectively reduces the risk of stroke and is recommended for chronic anticoagulation [1]. In AF patients with a CHADS2 score of 0–1 – where the risk of stroke may be lower – warfarin is more controversial, given its narrow therapeutic window and risk of major or life-threatening bleeding, and either warfarin or aspirin are recommended for chronic anticoagulation, according to patient and provider preferences [6,7]. Although widely used, several limitations exist with the classical CHADS2 scoring system. Anticoagulant selection for the “intermediate risk” group (score 1–2), encompassing >60% of patients, is determined by clinician preference [8] and fear of warfarin-related bleeding complications may result in suboptimal TE prophylaxis. Additionally, the CHADS2 scoring neglects other known AF-related stroke risk factors (female sex, age 65–74, peripheral arterial disease), and lacks validation in the peri-procedural period [8,9].

Table 1
The CHADS2 Scoring System.

AF ablation, if successful long-term, may reduce the risk of future stroke and transient ischemic attack (TIA). However, somewhat paradoxically, AF patients are at increased short-term risk of TE for several days, and up to four weeks, after their ablation [10]. This pro-thrombotic period may result in a higher, albeit transient, TE risk in AF patients who were previously judged to be low-risk. Although the precise mechanism(s) by which ablation induces this pro-thrombotic effect are not clearly understood, several factors are implicated. Transseptal sheath placement can precipitate thrombus formation on the catheter or sheath during the procedure (although catheter thrombus may be minimized with adequate peri-procedural anticoagulation and an open-irrigated tip) or in the left atrial appendage (LAA) [1113]. Delivery of radiofrequency energy during the ablation disrupts the endocardium, possibly exposing procoagulant proteins (e.g. tissue factor) and activating the clotting cascade [14]. “Char” (hard coagulum) from tissue heating and denaturation and aggregation of plasma proteins [15] may form and systemically embolize [11]. Additionally, the atrial tissue may be stunned for several weeks, or even months, post-procedure leading to impairment of normal contraction [16].

Reported rates of peri-procedural TE complications are 0.5–2.8% [11,1719] and may be higher in patients with a CHADS2 score ≥ 2, patients with a history of stroke [10], patients with persistent rather than paroxysmal AF [1], and patients with marked left atrial enlargement or a dilated LAA [20].

As the number of AF ablation procedures increases, especially in higher-risk and older patients, comprehensive and careful peri-procedural anticoagulation management based on best-available data and individualized for each patient is paramount. Although preprocedure warfarin (goal international normalized ratio [INR] 2–3) and intra-procedure intravenous unfractionated heparin (IV UFH) with a target activated clotting time (ACT) of ≥ 300 seconds are routinely used, practice patterns for other peri-procedural anticoagulation (e.g. post-procedure heparinoids, antiplatelet agents, and duration of warfarin) vary widely. These differences are due, in part, to a paucity of adequately powered studies and, in the studies published to date, heterogeneity in patient populations, type of bridging strategy employed, and outcomes. These limitations underscore the need for caution when interpreting published data and, in the authors’ opinion, the need for an individualized peri-procedural anticoagulation management plan for most patients. A more detailed list of the studies referred to in this review can be found in Appendix A.

Should AF patients receive pre-procedural bridging therapy?

Current guidelines recommend anticoagulating AF patients with warfarin (INR goal 2–3) for a minimum of 3 weeks prior to either electrical or chemical cardioversion [1,21]. Given the risk of peri-procedural TE events, expert consensus statements extend these recommendations to include ablation procedures [22]. For patients either refusing or who are intolerant to oral anticoagulation, antiplatelet agents, although less effective than warfarin in preventing TE, are a recommended alternative, especially in lower TE risk patients (i.e those with paroxysmal AF and/or a CHADS2 score of 0) [10,2325].

Warfarinmay be stopped, at the clinician's preference, 2–5 days prior to the procedure [10,11,23,24,2632]. Alternatively, and as is done at our center and others, warfarin may be continued during the procedure without interruption. In two studies of lower risk patients (mean INR ± standard deviation day of procedure 2.7 ± 0.5 and 2.8 ± 0.7), continuing warfarin during the procedure was not associated with an increased risk of peri-procedural bleeding [27,33].

In patients where warfarin is stopped several days pre-ablation, either IV UFH or low molecular weight heparins (LMWH) may be used as "bridge" therapy (e.g. between the timewarfarin is discontinued and the procedure begins) [10,2227,29,30,3436]. Given their ease of use outside the hospital, the lack of monitoring required, and their potential economic savings, LMWHs are emerging as the preferred agents for peri-procedural bridging in many patients [37].

Most published studies employing LMWHs pre-procedure have used enoxaparin dosed at either 1 mg/kg twice daily or a lower dose of 0.5 mg/kg twice daily. Enoxaparin 0.5 mg/kg twice daily is being used with increasing frequency due to the lower rate of femoral vascular complications when this dosing regimen is employed [10,27,30,31]. The last dose of LMWH should be given at least 24 hours prior to the procedure to minimize bleeding events, as recommended in national guidelines [10,24,27,29,37].

How is anticoagulation managed intra-procedurally?

To prevent thrombus formation, a loading dose of UFH (100 U/kg) followed by a continuous infusion (10 U/kg/hr) is often utilized. The ACT is monitored until therapeutic or as needed [22]. In a trial of 3 different ACT targets (250–300s, 300–350s, and 350–400s), there was a lower incidence of TE (stroke and TIA) when the two higher ACT targets were maintained [11]. Consistent with these data, current guidelines recommend a target ACT of at least 300–350s throughout the procedure [22,25], although additional TE risk factors (e.g. spontaneous echo contrast and marked atrial enlargement) may warrant higher ACT targets of 350–400s [34,38].

How can anticoagulation post-procedure be managed?

As with direct current cardioversion, the atria are often "stunned" following radiofrequency ablation [16] and anticoagulation may help prevent thrombus formation and, importantly, stroke and TIA. Many centers restart warfarin and/or heparinoids a few hours after the procedure or the evening of the procedure [10,11,18,22,25,2729,31,32,3941]. In patients with higher post-procedure bleeding-risk, the initial use of IV UFH until the morning after the procedure followed by a transition to LMWH [10,18,32,40,41] allows for easier and more rapid reversal of anticoagulation if an early bleeding complication occurs.

When transitioning to LMWH and restarting warfarin, enoxaparin may be initially used therapeutically (1 mg/kg twice daily in the first 24 hours post-procedure) and then decreased to 0.5 mg/kg twice daily until a therapeutic INR is achieved [31,39]. This approach was associated with a reduction in post-procedure femoral vascular complications compared to 5 days of therapeutic enoxaparin (5.7% vs 1.6%). Importantly, there were no procedure-related TE events in patients who received this lower-dose enoxaparin regimen and a very low incidence of other bleeding events such as hematomas and pseudoaneurysms [31]. Low rates of post-procedure ischemic stroke were also reported in a study of similar design and were higher in patients with a CHADS2 score ≥ 2 (odds ratio [OR] 7.1 vs. CHADS2=0) or a history of stroke (OR 9.5), although the absolute number of events was small (10/721 patients,1.4%) [10].

How do we Estimate Individual Bleeding Risk?

Although antithrombotic therapy effectively reduces TE risk, this benefit comes at the risk of increasing bleeding, especially in higher-risk patients. Several bleeding risk-assessment scales [4244] may help clinicians determine their patient's risk of bleeding, although none have been validated well enough to recommend the preferential use of one over another. One of these bleeding risk scales, called “HEMORR2-HAGES” [45], was developed using a cohort of elderly AF patients prescribed warfarin. HEMORR2HAGES also identifies subgroups at higher risk of bleeding, including those with liver disease, ethanol abuse, and reduced platelet count or function. Regardless of which risk assessment tool is employed, many of the unique bleeding risks associated with AF ablation (usually from accessing the vasculature - groin hematomas, retroperitoneal bleeding, hemopericardium, atrioesophageal fistula, etc) are not incorporated into any of these bleeding risk schemes. Rather than relying on just one of these bleeding risk assessment tools, we and others [44] recommend incorporating the presence of these bleeding risk factors (Table 2) into a patient's individual anticoagulation plan.

Table 2
Major risk factors associated with hemorrhage on anticoagulant therapy [4244].

What is the role of antiplatelet agents pre- and post-ablation?

Aspirin (ASA) has been used in lower-risk AF patients undergoing ablation, although its precise role as monotherapy and as combination therapy with warfarin remains controversial. In 207 patients with symptomatic AF (85% had paroxysmal AF and 88% had a CHADS2 score of 0–1), warfarin was discontinued 3 days prior to ablation and patients received ASA 325 mg daily. Warfarin was resumed on the day of procedure and both medications were continued for 6 weeks. TE events occurred in 2 patients (0.97%) within 8 days post-procedure, both with subtherapeutic INRs, and two patients had small groin hematomas post-procedure (0.97%) [28]. Thus, ASA may be an alternative to LMWH bridging to warfarin in AF patients with a low CHADS2 score and paroxysmal AF, although more data is clearly needed. ASA as monotherapy post-procedure may also be safe and effective in carefully selected low-risk AF patients (i.e. CHADS2 score of 0–1 and paroxysmal AF) [41], although the temporarily higher TE risk post-ablation may warrant warfarin as the preferred agent.

How long should patients remain anticoagulated after ablation?

The optimal duration of anticoagulation post-ablation ranges from one to six months depending on several variables, including stroke risk factors, CHADS2 score, [22,25,35], type of pre-procedure AF (persistent or paroxysmal) [28], and AF recurrence post-procedure [11,28,41,46,47]. Based on the high rate of asymptomatic AF after ablation [48] as well as the increased failure rates in patients with long-standing AF and/or those who have undergone multiple procedures [32,35,46], the duration of anticoagulation should be based largely on a patient's TE risk factors (i.e. CHADS2 score), as recommended in published guidelines [22,25]. The Venice Chart International Consensus Document on Atrial Fibrillation Ablation recommends that patients complete 3–6 months of warfarin. If the patient's CHADS2 score is ≥ 2, indefinite warfarin is recommended. For lower risk patients, either ASA or warfarin (CHADS2=1) or ASA or no therapy (CHADS2=0) are recommended [25]. Similarly, the Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society guidelines recommend at least 2 months of warfarin (INR 2–3) post-ablation followed by a duration of anticoagulation based on the patient's stroke risk factors [22]. Both guidelines recommend continuing warfarin indefinitely in any patients with a CHADS2 score ≥ 2 [22,25]. Interestingly, a recent study by Dagres and colleagues evaluated real-world adherence to these guidelines. The investigators found that AF recurrence was a more significant predictor for patients remaining on oral anticoagulation at 12 months post-ablation than the patient's CHADS2 score, possibly leading to overtreatment of low-risk patients, and undertreatment of high-risk patients [49].

Conclusions

Until large, adequately powered, randomized-controlled trials are available, practitioners must use the best available data and recommendations from consensus guidelines to understand how to safely and effectively reduce TE risk in AF patients undergoing ablation (Tables 3 and and4).4). Although no conclusive recommendations can be made, published guidelines and data support therapeutic anticoagulation (INR 2–3) for 3 weeks prior to ablation and use of IV UFH during the ablation itself (target ACT of at least 300–350s). Warfarinmay either be continued through the ablation or stopped 2–5 days prior to the ablation, depending on practitioner preference and institutional protocols. If the latter approach is chosen, the authors recommend a pre-ablation bridging strategy of enoxaparin 1 mg/kg twice daily unless the patient's bleeding risk dictates using the lower dose regimen (0.5 mg/kg twice daily).

Table 3
Summary of Peri-Procedural Anticoagulation Recommendations for Atrial Fibrillation Ablation.
Table 4
Summary of the Consensus Guidelines Statements on Peri-Procedural Anticoagulation in Atrial Fibrillation Ablation.

Bridging management strategies post-ablation are even less well standardized or studied, and current practice patterns are based largely on single-center experiences in smaller, non-randomized studies. No single strategy (either drug or dosing) has been shown to be unequivocally superior and LMWHs, IV UFH, and/or antiplatelet agents may be used until patients are therapeutic on warfarin. For lower risk patients (CHADS2 0–1), either warfarin or ASA may be utilized without bridging with a heparinoid. In higher TE risk patients (i.e. CHADS2 score ≥ 2), we recommend the use of therapeutic anticoagulation with either enoxaparin (1 mg/kg twice daily) or IV UFH for the first 12–24 hours. This recommendation places a larger emphasis on preventing TE events post-procedure and should be used thoughtfully, given the potential risk of bleeding. In patients with bleeding risk factors, enoxaparin may be subsequently reduced to 0.5 mg/kg until the INR is therapeutic, although the efficacy and pharmacology of this lower dosing regimen in stroke prevention has not been well studied and should be considered unproven until adequately powered and designed studies have been published. In accordance with national guidelines, warfarin should be continued post-ablation for a minimumof 2 months and then indefinitely in patients with a CHADS2 score ≥ 2.

Appendix A

Table 1

Clinical Trials Evaluating Peri-Procedural Anticoagulation for Atrial Fibrillation Ablation.

AuthorsPatientsPre-Procedural ACIntra-
Procedural
AC
Post-Procedural ACBleedingStroke/TIA
Schmidt, et al 2009 [33]n = 194


Follow-up:
Warfarin or phenprocoumon
either continued pre-
procedure or started 3 days
prior to procedure

Controls (n = 107): INR
<2 day of procedure

Cases (n = 87): INR ≥2 day
of procedure
Procedure postponed if INR
>3.5 day of procedure
ACT 350–450Controls: enoxaparin 0.5
mg/kg BID started 6–8
hours post-procedure
and continued until
therapeutic INR achieved
Warfarin or phenprocoumon
restarted in all patients
PM of procedure
Minor vascular
complicationsa
Controls: n = 7 (6.5%)
Cases: n = 5 (5.8%)
p = NS
Major vascular
complicationsb:

Controls: n = 1 (0.93%)
Cases: n = 1 (1.2%)
Controls: n = 0

Cases: n = 1 (1.2%)
Bunch, et al 2009 [41]n = 630


CHADS2 score
0–1: 20%
CHADS2 score
≥2: 80%
Mean follow-up:
327 ± 368 days
NRNRUFH 4 hours post-sheath
removal and continuing
for 24 hours
If CHADS2 score
0–1 = ASA 325 mg daily
(n = 123)

If CHADS2 score 2: LMWH
(dose NR) + warfarin
(n = 507)
NRASA group = 0%


Warfarin group = 0.4%

p = NS
Prudente, et al 2009 [31]n = 539
(603 procedures)
Mean follow-up:
1 month
Warfarin D/C 4 days pre-
procedure to achieve
INR <2
ACT 300–350Warfarin re-started 4–6
hours post-procedure
enoxaparin 1 mg/kg at
4 hours post-procedure
and the next AM
Protocol A (n = 263):
enoxaparin 1 mg/kg BID
× 5 additional days
Protocol B (n = 85):

enoxaparin 1 mg/kg BID
× 3 additional days
Protocol C (n = 255):
enoxaparin 0.5 mg/kg BID
× 3 additional days
Femoral vascular
complications:
Protocol A: 5.7%


Protocol B: 2.4%
Protocol C: 1.6%
p<0.03
(comparing A to B + C
or A to C)
Protocol A: n = 1 (0.38%)

Protocol B: n = 0


Protocol C: n = 0
Scherr, et al 2009 [10]n = 579
(721 procedures)

CHADS2 score 0–1:
580/721 (79)%
CHADS2 score ≥2:
152/721 (21%)
Follow-up: 3
months
Warfarin (INR 2–3) for at
least 4 weeks pre-ablation



Warfarin D/C 5 days pre-
procedure, and bridged
with enoxaparin
0.5–1 mg/kg BIDg
ACT 300–400Warfarin + UFH initiated
6 hours post-sheath
removal
UFH D/C and enoxaparin
0.5–1 mg/kg BIDc started
the following AM and
continued until INR >2
Warfarin continued for at
least 3 months
Pericardial effusions
n = 9/721 (1.2%)

Femoral vascular
complications
n = 11/721
(1.5%)
Within ≤30 days post-
procedure: n = 10/721
(1.4%) (9 were within 24
hours of procedure, 1
within 6 days of procedure)


CHADS2 score 0: 0.3%

CHADS2 score 1: 1.0%
CHADS2 score ≥2: 4.7%
Mortada, et al 2008 [28]n = 207

CHADS2 score 0–1:
88%
CHADS2 score ≥2:
12%

Mean follow-up:
24 ± 6 months
Warfarin D/C 3 days pre-
procedure, then ASA
325 mg daily × 3 days

Need
INR ≤2
ACT 300–350Warfarin (INR 2–3) and
ASA restarted day of
procedure and continued
for 6 weeks
Warfarin continued beyond
6 weeks only if pt had AF
recurrence or prior history
of persistent AF

If no AF recurrence at 6
months, warfarin D/C
ASA continued for at least
6 months in all patients
Groin hematoma
n = 2 (0.97%)
Pericardial effusion
n = 2 (0.97%)
n = 2 (0.97%)

CHADS2 scores 1, 2

Both events occurred within
8 days of procedure, both
with subtherapeutic INR
Rossillo, et al 2008 [47]n = 170

n = 85 undergoing
PVAI
(28% low-medium
stroke riskf; 72%
high stroke riskf)
n = 85 matched
controls
undergoing DCCV
(24% low-medium
stroke riskf; 76%
high stroke riskf)
Mean follow-up:
15 ± 7 months
AC started 1 month
pre- procedure
ACT 350–400ASA 325 mg × 1 dose given
at the end of procedure
All patients discharged
with warfarin × 3 months
Warfarin was D/C after
3 months unless patient
had one of the following:
recurrence of AF >60% PV
narrowing Poor atrial
contractility Presence of
other indications for AC
NRPVAI group n = 1 (1.2%)
(<30 days after procedure)
Control group

n = 5 (5.9%)


(1 <30 days after procedure,
4>30 days after procedure)
Nademanee, et al 2008 [29]n = 635 (1,065
procedures)


Age>65 or had
at least 1 stroke
risk factor
Mean follow-up:
836 ± 605 days
Warfarin (INR 2–3) for
at least 3 weeks pre-
procedure




Warfarin D/C 4 days
pre-procedure


If persistent or permanent
AF, bridged with
enoxaparin 1 mg/kg BID
NRWarfarin + enoxaparin 1
mg/kg BID restarted
immediately
post-procedure
Enoxaparin D/C 3 days
later

Warfarin D/C after 3
months if NSR maintained,
then ASA or clopidogrel
prescribed
Hemopericardium
n = 9/635 (1.4%)


Femoral vascular
complications
n = 13/635 (2%)
n = 11/517 (2.1%)



Patients who D/C warfarin
n = 5/434 (1.2%)

Patients who
continued warfarin
n = 6/83 (7.2%)

4 with adequate INRs 3
months prior, 2 had no
documented INR within
3 months of event
Seow, et al 2007 [32]n = 56 (86
procedures)



Mean follow-up:
21.6 ± 8.8 months
AC D/C 3–5 days pre-
procedure
ACT 300–350UFH 4 hours post-
procedure and continued
until the following AM,
then changed to LMWH
until INR >2
Warfarin re-started the
following AM
Cardiac tamponade
n = 1 (1.1%)
n = 2 (2.3%)
Wazni, et al 2007 [27]n = 355

Mean follow-up:
3–4 months
Groups 1 and 2: warfarin D/C
2–3 days prior to procedure








Group 3: warfarin continued
without interruption
(INR 2–3.5)
ACT 350–450ASA 325 mg × 1 dose at
the end of procedure



Warfarin restarted PM of
procedure


Group 1 (n = 105):


enoxaparin 1 mg/kg BID
until INR >2


Group 2 (n = 100):
enoxaparin 0.5 mg/kg BID
until INR >2
Group 3 (n = 150):
continued warfarin
(INR 2–3.5)
Minor bleedingd:

Group 1: n = 23 (22%)

Group 2: n = 19 (19%)
Group 3: n = 8 (5.3%)

p<0.001

Major bleedinge:


Group 1: n = 9
((8.6%)
Group 2: n = 0 (0%)
Group 3: n = 0 (0%)
p<0.001
Group 1: n = 1 (0.95%)



Group 2: n = 2 (2%)


Group 3: n = 0
p = NS
Oral, et al 2006 [30]n = 755

No stroke risk
factorsc: 44%
≥1 stroke risk
factorsc: 56%
Mean follow-up:
25 ± 8 months
Warfarin D/C 5 days pre-
procedure
ACT 300–350UFH 1000 units/hour
within 3 hours of sheath
removal, continued until
the following AM, then
changed to enoxaparin
0.5 mg/kg BID until INR ≥2
Warfarin restarted PM of
procedure and continued
for at least 3 months
ASA 81–325 mg daily
indefinitely after warfarin
D/C
Cerebral hemorrhage
n = 2 (0.3%)
≤30 days of ablation:
n = 7 (0.9%)
(1 intraprocedural, 3 on
enoxaparin with INR <2,


3 off enoxaparin with
INR ≤2)

>30 days post-ablation:
n = 2 (0.3%)
(both on warfarin with
INR 2.6–3.2)
Wazni, et al 2005 [11]n = 785

Follow-up:
12 months
Warfarin (INR 2–3)

D/C 48 hours pre-
procedure
Group 1:
(n = 194)
ACT 250–300
ASA × 1 dose at end of
procedure (dose NR)



Warfarin restarted day
of procedure
Groin hematoma:

Group 1: n = 1

Group 2: n = 2
Group 3: n = 2
Group 1: n = 7 (3.6%)




Group 2: n = 3 (1.7%)
Wazni, et al 2005 [11]Group 2:
(n = 180)
ACT 300–350 +
Eptifibatide

Group 3:
(n = 411)
ACT 350–400
If history of persistent
AF: enoxaparin 0.5 mg/kg
BID until therapeutic INR
achieved

Warfarin D/C after 4–6
months unless
AF recurrence or >70% PV
narrowing
Pericardial effusion:

Group 1: n = 1
Group 2: n = 1
Group 3: n = 0
Cardiac tamponade:

Group 1: n = 1

Group 2: n = 1
Group 3: n = 0


Group 3: n = 2 (0.49%)


All events were intra-
procedural

AC = anticoagulation; ACT = activated clotting time; AF = atrial fibrillation; AM = morning; ASA = aspirin; BID = twice daily; CHADS2 = stroke risk stratification system; D/C = discontinued; DCCV = direct current cardioversion; INR = international normalized ratio; LMWH = low-molecular weight heparin; NR = not reported; NSR = normal sinus rhythm; PM = evening; PV = pulmonary vein; PVAI = pulmonary vein antrum isolation; TIA = transient ischemic attack; UFH = unfractionated heparin.

aminor vascular complications defined as hematoma that did not require intervention;
bmajor vascular complications defined as hematoma that required intervention or bleeding that required blood product transfusions;
ccongestive heart failure, hypertension, age >65, diabetes mellitus, prior stroke or transient ischemic attack;
dhematoma not requiring intervention;
ecardiac tamponade, hematoma requiring intervention, bleeding requiring transfusion;
flow stroke risk defined as age <65, no hypertension, no diabetes, no congestive heart failure, no previous stroke; medium stroke risk defined as age >65, no hypertension, no diabetes, no congestive heart failure, no previous stroke; high stroke risk defined as age >65 plus hypertension or diabetes or congestive heart failure or previous stroke OR age >75 without other risk factors;
genoxaparin 1 mg/kg BID used from 2001–2004, but then was decreased to 0.5 mg/kg BID from 2005–2008 due to high incidence of vascular complications.

Footnotes

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

1. European Heart Rhythm Association, Heart Rhythm Society. Fuster V, Rydén LE, Cannom DS, Crijns HJ, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) J Am Coll Cardiol. 2006;48:854–906. [PubMed]
2. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457. [PubMed]
3. Bornstein N, Corea F, Galllai V, Parnetti L. Heart-brain relationship: atrial fibrillation and stroke. Clin Exp Hypertens. 2002;24:493–499. [PubMed]
4. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39:1901–1910. [PubMed]
5. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870. [PubMed]
6. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrialfibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501. [PubMed]
7. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287–2292. [PubMed]
8. Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest Sep. 2009;17 [Electronic publication ahead of print] [PubMed]
9. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156:57–64. [PubMed]
10. Scherr D, Sharma K, Dalal D, Spragg D, Chilukuri K, Cheng A, et al. Incidence and Predictors of Periprocedural Cerebrovascular Accident in Patients Undergoing Catheter Ablation of Atrial Fibrillation. 2009;20(12):1357–1363. [PubMed]
11. Wazni OM, Rossillo A, Marrouche NF, Saad EB, Martin DO, Bhargava M, et al. Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: impact of different anticoagulation regimens and importance of intracardiac echo imaging. J Cardiovasc Electrophysiol. 2005;16:576–581. [PubMed]
12. Dorwarth U, Fiek M, Remp T, Reithmann C, Dugas M, Steinbeck G, et al. Radiofrequency catheter ablation: different cooled and noncooled electrode systems induce specific lesion geometries and adverse effects profiles. Pacing Clin Electrophysiol. 2003;26:1438–1445. [PubMed]
13. Ren JF, Marchlinski FE, Callans DJ. Left atrial thrombus associated with ablation for atrial fibrillation: identification with intracardiac echocardiography. J Am Coll Cardiol. 2004;43:1861–1867. [PubMed]
14. Luther T, Mackman N. Tissue factor in the heart. Multiple roles in hemostasis, thrombosis, and inflammation. Trends Cardiovasc Med. 2001;11:307–312. [PubMed]
15. Demolin JM, Eick OJ, Münch K, Koullick E, Nakagawa H, Wittkampf FH. Soft thrombus formation in radiofrequency catheter ablation. Pacing Clin Electrophysiol. 2002;25:1219–1222. [PubMed]
16. Sparks PB, Jayaprakash S, Vohra JK, Mond HG, Yapanis AG, Grigg LE, et al. Left atrial "stunning" following radiofrequency catheter ablation of chronic atrial flutter. J Am Coll Cardiol. 1998;32:468–475. [PubMed]
17. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005;111:1100–1105. [PubMed]
18. Oral H, Chugh A, Ozaydin M, Good E, Fortino J, Sankaran S, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation. 2006;114:759–765. [PubMed]
19. Bertaglia E, Zoppo F, Tondo C, Colella A, Mantovan R, Senatore G, et al. Early complications of pulmonary vein catheter ablation for atrialfibrillation: amulticenter prospective registry on procedural safety. Heart Rhythm. 2007:1265–1271. [PubMed]
20. Sakurai K, Hirai T, Nakagawa K, Kameyama T, Nozawa T, Asanoi H, et al. Left atrial appendage function and abnormal hypercoagulability in patients with atrial flutter. Chest. 2003;124:1670–1674. [PubMed]
21. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133:546S–592S. [PubMed]
22. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace. 2007;9:335–379. [PubMed]
23. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study) Eur Heart J. 2006;27:216–221. [PubMed]
24. Scherr D, Dalal D, Chilukuri K, Dong J, Spragg D, Henrikson CA, et al. Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2009;20:379–384. [PubMed]
25. Natale A, Raviele A, Arentz T, Calkins H, Chen SA, Haïssaguerre M, et al. Venice Chart international consensus document on atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2007;18:560–580. [PubMed]
26. Scheinman M, Calkins H, Gillette P, Klein R, Lerman BB, Morady F, et al. NASPE policy statement on catheter ablation: personnel, policy, procedures, and therapeutic recommendations. Pacing Clin Electrophysiol. 2003;26:789–799. [PubMed]
27. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation. 2007;116:2531–2534. [PubMed]
28. Mortada ME, Chandrasekaran K, Nangia V, Dhala A, Blanck Z, Cooley R, et al. Periprocedural anticoagulation for atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2008;19:362–366. [PubMed]
29. Nademanee K, Schwab MC, Kosar EM, Karwecki M, Moran MD, Visessook N, et al. Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2008;51:843–849. [PubMed]
30. Oral H, Chugh A, Ozaydin M, Good E, Fortino J, Sankaran S, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation. 2006;114:759–765. [PubMed]
31. Prudente LA, Moorman JR, Lake D, Xiao Y, Greebaum H, Mangrum JM, et al. Femoral vascular complications following catheter ablation of atrial fibrillation. J Interv Card Electrophysiol. 2009;26:59–64. [PubMed]
32. Seow SC, Lim TW, Koay CH, Ross DL, Thomas SP. Efficacy and late recurrences with wide electrical pulmonary vein isolation for persistent and permanent atrial fibrillation. Europace. 2007;9:1129–1133. [PubMed]
33. Schmidt M, Segerson NM, Marschang H, Akoum N, Rittger H, Clifford SM, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol. 2009;32:995–999. [PubMed]
34. Ren JF, Marchlinski FE, Callans DJ, Gerstenfeld EP, Dixit S, Lin D, et al. Increased intensity of anticoagulation may reduce risk of thrombusduring atrial fibrillation ablation procedures in patients with spontaneous echo contrast. J Cardiovasc Electrophysiol. 2005;16:474–477. [PubMed]
35. Shah AN, Mittal S, Sichrovsky TC, Cotiga D, Arshad A, Maleki K, et al. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol. 2008;19:661–667. [PubMed]
36. He H, Kang J, Tao H, Zhen B, Zhang M, Long D, et al. Conventional oral anticoagulation may not replace prior transesophageal echocardiography for the patients with planned catheter ablation for atrial fibrillation. J Interv Card Electrophysiol. 2009;24:19–26. [PubMed]
37. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133:299S–339S. [PubMed]
38. Pappone C, Santinelli V. The who, what, why, and how-to guide for circumferential pulmonary vein ablation. J Cardiovasc Electrophysiol. 2004;15:1226–1230. [PubMed]
39. Shea JB. Anticoagulation practice in cardiac electrophysiology. Heart Rhythm. 2006;3:372–374. [PubMed]
40. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F, Jr, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006;354:934–941. [PubMed]
41. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, et al. Warfarin Is Not Needed in Low-Risk Patients Following Atrial Fibrillation Ablation Procedures. J Cardiovasc Electrophysiol. 2009;20:988–993. [PubMed]
42. Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G, et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med. 2003;163:917–920. [PubMed]
43. Kuijer PM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457–460. [PubMed]
44. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl JMed. 2003;349:631–639. [PubMed]
45. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J. 2006;151:713–719. [PubMed]
46. Katritsis D, Wood MA, Giazitzoglou E, Shepard RK, Kourlaba G, Ellenbogen KA. Long-term follow-up after radiofrequency catheter ablation for atrial fibrillation. Europace. 2008;10:419–424. [PubMed]
47. Rossillo A, Bonso A, Themistoclakis S, Riccio G, Madalosso M, Corrado A, et al. Role of anticoagulation therapy after pulmonary vein antrum isolation for atrial fibrillation treatment. J Cardiovasc Med (Hagerstown) 2008;9:51–55. [PubMed]
48. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation. 2005;112:307–313. [PubMed]
49. Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K, et al. Real-life anticoagulation treatment of atrial fibrillation after catheter ablation: Possible overtreatment of low-risk patients. Thromb Haemost. 2009;102:754–758. [PubMed]